{
    "title": "Sanofi in hunt for specialty drugs with $3.7 bln deal for U.S.-based Principia",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8634591/Sanofi-snags-U-S-biotech-asset-3-7-bln-deal-Principia-Biopharma.html",
    "date": "2020-08-17",
    "keywords": [
        "pemphigus",
        "hudson",
        "drug",
        "sanofi",
        "deal",
        "acquisition",
        "autoimmune",
        "sclerosis",
        "cash",
        "bolton",
        "year",
        "candidate",
        "rilzabrutinib",
        "executive",
        "paul",
        "principia",
        "biopharma",
        "inc",
        "cabinet",
        "drugmaker",
        "pipeline",
        "condition",
        "share",
        "premium",
        "closing",
        "price",
        "aug",
        "completion",
        "helm",
        "stake",
        "regeneron",
        "game",
        "plan",
        "division",
        "treatment",
        "transaction",
        "purchase",
        "ceo",
        "december",
        "synthorx",
        "phase",
        "skin",
        "immune",
        "system",
        "body",
        "rampd",
        "transformation",
        "development",
        "statement",
        "principias",
        "roche",
        "rituxan",
        "fall",
        "index",
        "cac40s",
        "drop",
        "strategy",
        "brokerage",
        "buy",
        "evercore",
        "advisor",
        "centerview",
        "sudip",
        "kargupta",
        "john",
        "miller",
        "editing",
        "rashmi",
        "aich",
        "fenton"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}